MARKET WIRETradingView • 10h ago
Surrozen, Inc. Estimates – NASDAQ:SRZNTradingView report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
Why SRZN Stock slipped -1.43% Today — RQD Quant Desk Flash
$29.04 -1.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $28.91
Surrozen Inc. (SRZN) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $524.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SRZN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SRZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Surrozen Inc. (NASDAQ: SRZN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $29.04 (-1.43% 1D, market cap $524.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SRZN ranks #577 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SRZN compare to VALN and ETRA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRZN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VALN (Valneva SE) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $541.8M) and ETRA (Electra Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $542.3M). Among the 5-stock peer group, SRZN leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SRZN?
▼
Per SRZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001824893), Surrozen Inc. generated $3.5M in revenue (-67.4% YoY), -$242.0M in net income, and -$30.4M in free cash flow against $98.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $28.91 (-0.45%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRZN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY SRZN SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (37% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$24.76-3.7% Next Q
30
Q2 (-2Q)Grade E$23.84+14.4% Next Q
33
Q3 (-1Q)Grade E$27.28+6.5% Next Q
35
CurrentGrade D-$29.04-7.8% Hist 90D α
38
Trajectory: E (30) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SRZN Turnaround Squeeze
While SRZN currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.42) and Max Pain ($30.49) forces dealer call-delta covering toward $39.72.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SRZN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SRZN Stock slipped -1.43% Today — RQD Quant Desk Flash
Surrozen Inc. (SRZN) slipped -1.43% to $29.04, trading at 67% of its 52-week range ($11.39 – $37.83). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 67% of its 52-week range ($11.39 – $37.83) with RSI-14 at 59.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $29.04 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SRZN Headlines & Catalysts
MARKET WIREStock Titan • 13h ago
A director and a venture investor each report the same stake in Surrozen (SRZN).Stock Titan report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 16h ago
13 Biotech Stocks to Watch: Candel (NASDAQ:CADL), Verastem (NASDAQ:VSTM), Surrozen (NASDAQ:SRZN) and Ten Other Nasdaq Biotech Stockskalkine.ca report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 19h ago
Surrozen (SRZN) Stock Screener: -5.05% Decline on Elevated Volume 2026-10-14 - Rating Changehttps://www.siam.in/ report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 22h ago
Surrozen Inc. (SRZN) Q2 2026 Earnings: Narrower-Than-Expected Loss Meets a Muted Market Response - Negative Surprise Momentumhttps://www.dars.gov.et/ report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 1d ago
Surrozen (SRZN) Jumps 5.56% to $25.07 as Biotech Name Tests Upper Range - MA Crossoverhttps://www.siam.in/ report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Surrozen (SRZN) Ticks Up 1.71% to $23.84 as Shares Press Toward Resistance - Composite Profilehttps://www.siam.in/ report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 13d ago
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 MillionProceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq
MARKET WIREYahoo • 18d ago
Top Biotech Stock: Guggenheim Names Surrozen as Best PickInvesting.com -- Guggenheim Securities has identified Surrozen, Inc. as its top pick in the biotechnology sector, assigning a Buy rating with a price target of $42.00. The firm hosted management from Surrozen to discuss
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRZN)
- ✓Walkthrough of SRZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SRZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.45%📐 HORIZONTAL RANGE
2026-11-02O $30.35H $30.35L $29.04C $29.04VOL 254.7K
RES: $42.68SUP: $14.72SMA50: $24.42SMA200: $25.15
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SRZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SRZN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SRZN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SRZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRZN)
Health Care Rank #577 of 1016
⚔️ VALN vs SRZN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SRZN vs. VALN, ETRA, ENTX, RGNX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Surrozen Inc. (SRZN) ranks #577 by composite RQD confidence (38/100, grade D-) and #438 by equity capitalization ($524.4M). Within this direct 5-issuer industry benchmark cohort, SRZN leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with SRZN at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SRZN
ACTIVE
Surrozen Inc. | D- | 38/100 | — | — | -35.0% | -1.43% | $524.4M | Benchmark Subject |
| VALN Valneva SE | D | 48/100 | — | — | — | -4.55% | $541.8M | /valn-vs-srzn → |
| ETRA Electra Therapeutics Inc. | D- | 43/100 | — | — | — | -6.25% | $542.3M | /etra-vs-srzn → |
| ENTX Entera Bio Ltd. | D- | 40/100 | — | 0.0% | -33.6% | +2.56% | $542.6M | /entx-vs-srzn → |
| RGNX REGENXBIO Inc. | E | 27/100 | — | — | -35.0% | -2.83% | $489.2M | /rgnx-vs-srzn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001824893In its most recent audited fiscal period (FY2025, filed 2025-12-31), Surrozen Inc. (SRZN) reported GAAP revenue of $3.5M (-67.4% vs. FY2024 revenue of $10.7M ) , GAAP net income of -$242.0M, operating cash flow of -$30.2M, and free cash flow of -$30.4M (-72.0% YoY). On the balance sheet, SRZN closed FY2025 with $98.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.5M | -$242.0M | -$30.2M | -$30.4M | $98.7M | — |
| FY2024 (FY) | 2024-12-31 | $10.7M | -$63.6M | -$17.6M | -$17.7M | $48.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$43.0M | -$40.4M | -$40.4M | — | — |
3. SRZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SRZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Surrozen Inc. (NASDAQ: SRZN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $29.04 (-1.43% 1D, market cap $524.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SRZN ranks #577 in composite RQD confidence.
How does SRZN compare to VALN and ETRA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRZN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VALN (Valneva SE) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $541.8M) and ETRA (Electra Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $542.3M). Among the 5-stock peer group, SRZN leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SRZN?
Per SRZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001824893), Surrozen Inc. generated $3.5M in revenue (-67.4% YoY), -$242.0M in net income, and -$30.4M in free cash flow against $98.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SRZN trading relative to its 50-day, 200-day, and 52-week technical levels?
SRZN last traded at $29.04 (-1.43% on volume of 231,875 shares), positioning the stock +18.92% above its 50-day simple moving average ($24.42) and +15.47% above its 200-day simple moving average ($25.15). Across its 52-week range of $11.39 to $37.83, SRZN sits at the 66.8% percentile with a 14-day RSI of 59.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($25.41 to $32.67).
SRZN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SRZN stock moving today?
Why SRZN Stock slipped -1.43% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 38/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
SRZN — Surrozen Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:35:26Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, Surrozen Inc. scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine: 8 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is -5.79%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or positive free cash flow, so valuation rests on future outcomes rather than current earnings power.
- Whale 13F Flow: 14 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. This is the strongest pillar and suggests some institutional interest, though the underlying 13F holder detail is not itemized in the source data.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider conviction signals in the data.
- Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 means the stock is expected to move roughly with the market, with no defensive cushion indicated.
- Forensic Balance Sheet: 5 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings point to meaningful balance sheet and financial-quality concerns.
Investor implications: the upside case depends on the institutional-flow pillar and on whether the company's cash reserves can bridge losses long enough for operating performance to improve. Valuation is hard to anchor because P/E and EV/EBITDA are not available in source data, and EPS is not available either. The weak forensic and insider scores are the main reasons the rating is in the sell range. This is an educational reading of the rating, not personalized advice.
Business
Surrozen Inc. is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the profile. Per the market data, its gross margin is 0%. The source data does not describe specific products, customers, or revenue model. Per the SEC financials, FY 2025 revenue was $3.5M, indicating minimal current commercial revenue.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $-42.1M | $-242.0M | N/A | $-30.4M | $89.2M | N/A |
| FY 2024 | $10.7M | $-25.5M | $-63.6M | N/A | $-17.7M | $34.6M | N/A |
| FY 2023 | $0.0M | $-45.8M | $-43.0M | N/A | $-40.4M | N/A | N/A |
Per the SEC financials and market data, operating margin and net margin are both -60%, and ROIC is -35%. Per the Roarable RQD rating, Altman Z is 2.5 and Piotroski F is 2/9, with Debt/Equity at 0.5. Reported cash rose from $34.6M in FY 2024 to $89.2M in FY 2025 even as FY 2025 net loss was $-242.0M. Debt is not available in source data for any period.
Recent Catalysts & News Wire Analysis
Per the recent news wire, five items are listed, all tagged to SRZN:
- CATALYST (green): A Stock Titan item reporting a 5.56% move to $25.07 and an MA crossover. The item is labeled as a catalyst, but the source does not detail the cause of the move.
- RISK WATCH (red): A report on Q2 2026 earnings describing a narrower-than-expected loss alongside a muted market response, tagged "negative surprise momentum." The headline mixes a favorable loss comparison with a negative market reaction.
- MARKET WIRE (yellow): Items covering a 2026-10-14 decline of -5.05% on elevated volume, a director and a venture investor reporting the same stake, and a biotech stock list that includes SRZN.
The Butterfly Supply-Chain Graph lists supply chain as "NONE," with no butterfly links and no proprietary signals.
Open Questions
- What specific programs or products generate the FY 2025 revenue of $3.5M, and what drove the net loss of $-242.0M relative to operating loss of $-42.1M?
- What is the company's debt position, since debt is listed as N/A across all periods?
- What is the EPS, and what would P/E and EV/EBITDA look like once those metrics are available?
- What caused the 5.56% move to $25.07 and the -5.05% decline on elevated volume noted in the news wire?
- Who are the institutional and insider holders behind the whale-flow and Form 4 signals in the RQD rating?
SRZN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Surrozen Inc. (SRZN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 10h ago
Surrozen, Inc. Estimates – NASDAQ:SRZN TradingView report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 13h ago
A director and a venture investor each report the same stake in Surrozen (SRZN). Stock Titan report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 16h ago
13 Biotech Stocks to Watch: Candel (NASDAQ:CADL), Verastem (NASDAQ:VSTM), Surrozen (NASDAQ:SRZN) and Ten Other Nasdaq Biotech Stocks kalkine.ca report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 19h ago
Surrozen (SRZN) Stock Screener: -5.05% Decline on Elevated Volume 2026-10-14 - Rating Change https://www.siam.in/ report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 22h ago
Surrozen Inc. (SRZN) Q2 2026 Earnings: Narrower-Than-Expected Loss Meets a Muted Market Response - Negative Surprise Momentum https://www.dars.gov.et/ report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 1d ago
Surrozen (SRZN) Jumps 5.56% to $25.07 as Biotech Name Tests Upper Range - MA Crossover https://www.siam.in/ report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Surrozen (SRZN) Ticks Up 1.71% to $23.84 as Shares Press Toward Resistance - Composite Profile https://www.siam.in/ report covering Surrozen Inc. (SRZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 13d ago
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million Proceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SRZN Bull vs. Bear Conversation Board — What's Your Call at $29.04?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SRZN 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $25.92 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is SRZN (D- • RQD 38/100) a Buy at $29.46?
Welcome to the SRZN (Surrozen Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $24.75 (-16.0%)
Spot @ $29.46 Pump the brakes on SRZN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on SRZN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Surrozen Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $35.06 (+19.0%)
Spot @ $29.46 SRZN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on SRZN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $29.46 (52-wk range $11.39 - $37.83), any beat on forward guidance forces shorts and underweight funds to chase.